[Skip to Content]
[Skip to Content Landing]
Views 260
Citations 0
Comment & Response
June 20, 2019

Time to Change the Limited-Stage Paradigm for Small Cell Lung Cancer?—In Reply

Author Affiliations
  • 1Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom
  • 2Clinical Oncology Department, Christie NHS Foundation Trust, Manchester, United Kingdom
JAMA Oncol. 2019;5(8):1229-1230. doi:10.1001/jamaoncol.2019.1332

In Reply We thank Chun et al for their letter and interest in the CONVERT trial1 and the early stage subgroup analysis2 published in JAMA Oncology. To date, most improvements in limited-stage small cell lung cancer management have been in the area of radiotherapy, highlighting its integral role in the management of this disease. We agree with Chun and colleagues on the importance of high-quality evidence from well-designed and executed randomized trials in small cell lung cancer. We eagerly await results from the CALGB 30610/NRG Oncology-RTOG 0538 trial (NCT00632853), which will further inform the care of limited-stage small cell lung cancer.

×